Trial Profile
A randomized, double-blind, placebo controlled study to assess the safety and the efficacy of Neridronate ampoules 25 mg, after repeated intramuscular administrations, in patients with Complex Regional Pain Syndrome type I (CRPS-I)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2020
Price :
$35
*
At a glance
- Drugs Neridronic acid (Primary)
- Indications Complex regional pain syndromes
- Focus Therapeutic Use
- Sponsors Abiogen Pharma
- 28 Nov 2020 Status changed from recruiting to completed.
- 20 May 2015 New trial record